Pharma Marketing News
PMN Home | Advertising Information | FAQs
About Us | Contact Us | Privacy Policy
Subscribe Glossary
Pharma Marketing Blog Pharmaguy Audio Podcasts Event Calendar PReader Surveys

Share |

Brave New World of Off-Label Marketing
After the Fire Comes the Flood

Fire, Then FloodFDA's authority to prevent or even regulate off-label promotion by pharmaceutical companies is dwindling. After losing to Amarin in court, FDA suffered another setback when it settled a case with Pacira Pharmaceuticals. In both cases, the plaintiffs argued that off-label marketing was protected free speech as long as the information was truthful and not misleading. While the FDA still insists it has the ultimate authority to decide what is and is not truthful, other entities have claimed a stake in the debate.

This article summarizes various scenarios for how the FDA, courts, and independent 3rd-parties may influence off-label drug promotion in the future.

Topics (partial list):
  • Avoiding Off-Label Chaos
  • External Entity Review
  • Judicial Off-Label Activism
  • Crying Fire!
  • Figure: Drug ADEs and Off-Label vs. On-Label Prescribing
  • The Coming Flood

Download the full article (PDF file) here:

Issue: Vol. 15, No. 2: March 2016

Find other articles in related Topic Areas:

Vol 15, #2 Contents

Contact Information
Pharma Marketing News

Pharma Marketing News | Subscribe | Industry Insights | Podcasts | Pharmaguy | Blog
Surveys | Glossary | Conference Calendar | Advertising Information | FAQs | About Us | Privacy Policy

© 2016. Pharma Marketing Network. All rights reserved.